Cart
sales@molnova.com
KT-362 free base
CAS No. 93392-97-3
KT-362 free base( —— )
Catalog No. M36550 CAS No. 93392-97-3
KT-362 is a calcium channel blocker with antihypertensive properties that can be used in the study of cardiovascular disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 174 | In Stock |
|
| 10MG | 258 | In Stock |
|
| 25MG | 392 | In Stock |
|
| 50MG | 551 | In Stock |
|
| 100MG | 762 | In Stock |
|
| 200MG | 1014 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKT-362 free base
-
NoteResearch use only, not for human use.
-
Brief DescriptionKT-362 is a calcium channel blocker with antihypertensive properties that can be used in the study of cardiovascular disease.
-
DescriptionKT-362 is a calcium channel blocker with antihypertensive properties that can be used in the study of cardiovascular disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorCalcium Channel
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number93392-97-3
-
Formula Weight400.53
-
Molecular FormulaC22H28N2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(CCNCCC1=CC(OC)=C(OC)C=C1)(=O)N2C=3C(=CC=CC3)SCCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Praziquantel
Praziquantel is an anthelmintic effective against flatworms.
-
DS16570511 B
DS16570511 is a novel, cell-permeable inhibitor targeting the mitochondrial calcium uniporter. It effectively blocks the increase in Ca2+ influx dependent on MCU or MICU1 .
-
TTA-Q6
TTA-Q6, a selective T-type Ca2+ channel antagonist, exhibits potential antitumor and immunomodulatory activities for treating neurological disorders by inhibiting the uptake of extracellular calcium ions by tumor cells, thereby inducing intracellular calcium deficiency and endoplasmic reticulum (ER) stress.
